

33. The antibody of Claim 31 wherein the antibody is a humanized form of said antibody.

34. The antibody of Claim 31 wherein the antibody is a chimeric form of said antibody.

35. A cell line which produces an antibody which binds to the same epitope on human lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423.

36. A process for producing an antibody comprising:

producing an antibody by culturing the cell line of Claim 35.

37. The antibody of Claim 31 wherein said antibody elicits alloantigen specific hyporesponsiveness.

38. A composition, comprising:

(a) an antibody which binds to the same epitope on human lymphocytes as the antibody produced by the cell line deposited as ATCC HB 11423; and

(b) a pharmaceutically acceptable carrier, wherein said antibody is present in said composition in an amount effective to inhibit a T-cell mediated immune response.

39. The composition of Claim 38 wherein the antibody is a monoclonal antibody.

40. The composition of Claim 39 wherein the antibody is a rat antibody.

41. The composition of Claim 39 wherein the antibody is a humanized form of said antibody.

42. The antibody of Claim 39 wherein the antibody is a chimeric form of said antibody.

43. The composition of Claim 38 wherein said antibody is present in said composition in an amount effective to elicit alloantigen specific hyporesponsiveness.

REMARKS

The above is a preliminary amendment to the continuation application of application Serial No. 08/472,281, filed June 7, 1995. Claims 1-29 have been cancelled without prejudice